

<p>INFORMATION DISCLOSURE CITATION</p> <p>PTO-1449</p>	ATTORNEY'S DKT NO. 002010-586	APPLICATION NO. Unassigned 09/916,440
	APPLICANT Jing Wu, et al.	
	FILING DATE <u>Filed Herewith</u> 7/30/01	GROUP Unassigned 1624

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
<p>B.K.</p> <p>↓</p>	3,657,341	4/18/72	Thorne, et al.	260	558	<p>PTC</p> <p>10997 U.S. PATC</p> <p>09/916440</p>
	4,080,449	3/21/78	Croissier, et al.	424	244	
	4,477,464	10/16/84	Slade, et al.	424	275	
	4,666,829	5/19/87	Glenner, et al.	435	6	
	4,977,168	12/11/90	Bernat, et al.	514	330	
	5,238,932	8/24/93	Flynn, et al.	514	214	
	5,283,241	2/1/94	Bochis, et al.	514	183	
	5,284,841	2/8/94	Chu, et al.	514	183	
	5,324,726	6/28/94	Bock, et al.	514	221	
	5,360,802	11/1/94	Chambers, et al.	514	221	
	5,420,271	5/30/95	Warchawsky, et al.	540	521	
	5,556,969	9/17/96	Chambers, et al.	540	509	
	5,633,251	5/27/97	Claremon, et al.	514	221	
	5,658,901	8/19/97	Claremon, et al.	514	221	
	5,712,397	1/27/98	Esser, et al.	546	90	
5,770,573	6/23/98	Arrhenius, et al.	514	18		

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
<p>B.K.</p> <p>↓</p>	1 063 108	9/25/79	Canada	—	—		
	0 167 919	1/15/86	Europe	—	—		
	0 284 256	9/28/88	Europe	—	—		
	0 349 949	1/10/90	Europe	—	—		

INFORMATION DISCLOSURE CITATION

PTO-1449

 ATTORNEY'S DKT NO.
002010-586

APPLICATION NO.

~~Unassigned~~
09/916,440

 APPLICANT
Jing Wu, et al.

 FILING DATE
Filed Herewith 7/30/01

 GROUP
~~Unassigned~~ 1624

<i>D.K.</i>	0 376 849	7/4/90	Europe				
	0 434 360	6/26/91	Europe				
	0 434 364	6/26/91	Europe				
	0 434 369	6/26/91	Europe				
	0 490 590	6/17/92	Europe				
	0 514 133	11/19/92	Europe				
	0 523 845	1/20/93	Europe				
	0 549 039	6/30/93	Europe				
	0 647 632	4/12/95	Europe				
	0 652 009	6/10/95	Europe				
	0 667 344	8/16/95	Europe				
	0 677 517	10/18/95	Europe				
	0 732 399	9/18/96	Europe				
	0 778 266	11/6/97	Europe				
	1 519 931	7/6/78	Great Britain				
	1 573 931	8/18/80	Great Britain				
	2 272 439	5/18/94	Great Britain				
	2 290 788	1/10/96	Great Britain				
	04210967	8/3/94	Japan				
	06145148	5/24/94	Japan				
	07304770	11/21/95	Japan				
	10072444	3/17/98	Japan				
	92/01683	2/6/92	WIPO				
	92/16524	10/1/92	WIPO				
	93/19052	9/30/93	WIPO				
	93/19063	9/30/93	WIPO				
	94/05693	3/17/94	WIPO				
	94/04531	3/3/94	WIPO				
	94/07486	4/14/94	WIPO				
	94/10569	5/11/94	WIPO				

INFORMATION DISCLOSURE CITATION

PTO-1449

ATTORNEY'S DKT NO. 002010-586	APPLICATION NO. Unassigned 07/916, 440
APPLICANT Jing Wu, et al.	
FILING DATE Filed Herewith 7/30/01	GROUP Unassigned 1624

B.K.	95/03289	2/2/95	WIPO				
↓	95/03290	2/2/90	WIPO				
	95/09838	4/13/95	WIPO				
	95/14671	6/1/95	WIPO				
	95/21840	8/17/95	WIPO				
	95/23810	9/8/95	WIPO				
	95/25118	9/21/95	WIPO				
	95/32191	11/30/95	WIPO				
	96/05839	2/29/96	WIPO				
	96/16981	6/6/96	WIPO				
	96/19492	6/27/96	WIPO				
	96/20725	7/11/96	WIPO				
	96/22966	8/1/96	WIPO				
	96/40146	12/19/96	WIPO				
	96/40653	12/19/96	WIPO				
	96/40654	12/19/96	WIPO				
	96/40655	12/19/96	WIPO				
	96/40656	12/19/96	WIPO				
	97/30072	8/21/97	WIPO				
	97/38705	10/23/97	WIPO				
	98/00405	1/8/98	WIPO				
98/25930	6/18/98	WIPO					
98/28268	7/2/98	WIPO					
98/38177	9/3/98	WIPO					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

B.K.	Aquino, et al. "Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity. 1. Optimization of the Agonist "Trigger." <i>J. Med. Chem.</i> 39: 562-569 (1996).
------	--


INFORMATION DISCLOSURE CITATION		ATTORNEY'S DKT NO.	APPLICATION NO.
		002010-586	Unassigned 09/916 440
		APPLICANT	
PTO-1449		Jing Wu, et al.	
		FILING DATE	GROUP
		Filed Herewith 7/20/01	Unassigned-1624
B.K.	Arienti, et al. "Regioselective Electrophilic Alkylation of Anilines with Phanylacetylene in the Presence of Montmorillonite KSF." <i>Tetrahedron</i> 53(10): 3795-3804 (1997).		
	Bock, et al. "Synthesis and Resolution of 3-Amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones." <i>J. Org. Chem.</i> 52: 3232-3239 (1987).		
	Bock, et al. "An Expedient Synthesis of 3-Amino-1,3-Dihydro-5-Phenyl-2H-1,4-Benzodiazepin-2-one." <i>Tet. Lets.</i> 28(9): 939-942 (1987).		
	Bock, et al. "Selective Non-Peptide Ligands for an Accommodating Peptide Receptor. Imidazobenzodiazepines as Potent Cholecystokinin Type B Receptor Antagonists." <i>Bioorg. and Med. Chem. Lets.</i> 2(9):987-998 (1994).		
	Brown, et al. "A Revision of the structure of "7-Phenyloxindole"; Photochemical Synthesis and Pyrolytic Behaviour of Authentic 7-Phenyloxindole." <i>Tet. Lets.</i> 8: 667-670 (1971).		
	Chambers, et al. L-708,474: the C5-Cyclohexyl Analogue of L-365,260, A Selective High Affinity Ligand for the CCKB/Gastrin Receptor." <i>Bioorg. and Med. Chem. Lets.</i> 3(10):1919-1924 (1993).		
	Cordell. "B-Amyloid Formation as a Potential Therapeutic Target for Alzheimer's Disease." <i>Ann. Rev. Pharmacol. Toxicol.</i> 34:69-89 (1994).		
	Evans, et al. "Methods for Drug Discovery: Development of Potent, Selective Orally Effective Cholecystokinin Antagonists." <i>J. Med. Chem.</i> 31:2235-2246 (1988).		
	Evans, et al. "Molecular Mimicry and the Design of Peptidomimetics." <i>Molecular Mimicry in Health and Disease.</i> (A. Lernmark, et al., eds.) Elsevier Science Publishers B.v. (Biomedical Division) (1988) pp. 23-34.		
	Finizia, et al. "Synthesis and Evaluation of Novel 1,5-Benzodiazepines as potent and selective CCK-B Ligands, Effect of the Substitution of the N-5 Phenyl with Alkyl Groups." <i>Bioorg. & Medicinal Chemistry Letters.</i> 6(24):2957-2962 (1996).		
	Hirst, et al. "Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonists Activity (II): Optimization of the C3 Amino Substituent." <i>J. Med. Chem.</i> 39: 5236-5245 (1996).		
	Hofmann, et al. "Interactions of Benzodiazepine Derivatives with Annexins." <i>J. Biol. Chem.</i> 273(5):2885-2894 (1998).		
	Katritzky, et al. "Benzodiazepine Derivatives with Annexins." <i>J. Biol. Chem.</i> 273(5): 2885-2894 (1998).		
	Lowe, et al. "A Water Soluble Benzazepine Cholecystokinin-B-Receptor Antagonist." <i>Bioorg. and Med. Chem. Lets.</i> 5(17): 1933-1936 (1995).		
	Lowe, et al. "5-Phenyl-3-ureidobenzazepin-2-ones as Cholecystokinin-B Receptor Antagonists." <i>J. Med. Chem.</i> 37: 3789-3811 (1994).		
	Milligan, et al. "Intramolecular Schmidt Reactions of Alkyl Azides with Ketones: Scope and Stereochemical Studies." <i>J. Am. Chem. Soc.</i> 117: 10449-10459 (1995).		
	Papadopoulos, et al. Anodic Oxidation of N-Acyl and N-Alkoxy-carbonyl Dipeptide Esters as a Key Step for the Formation of Chiral Heterocyclic Synthetic Building Blocks." <i>Tetrahedron</i> 47(4/5):563-572 (1991).		
↓	Patel, et al. "Biological Properties of the Benzodiazepine Amidine Derivative L-740,093, a Cholecystokinin-B/Gastrin Receptor Antagonist with High Affinity in vitro and High Potency in vivo." <i>Molecular Pharmacology.</i> 46:943-948 (1994).		

INFORMATION DISCLOSURE CITATION		ATTORNEY'S DKT NO.	APPLICATION NO.		
		PTO-1449		002010-586	Unassigned 09/9/16, 440
				APPLICANT Jing Wu, et al.	
		FILING DATE Filed Herewith 7/30/02	GROUP Unassigned 1624		
B.K.	Reiter, et al. "Crystallization-Induced Asymmetric Transformation: Stereospecific Synthesis of a Potent Peripheral CCK Antagonist." <i>J. Org. Chem.</i> 52: 955-957 (1987).				
	Rittle, et al. "A New Amine Resolution Method and its Application to 3-Aminobenzodiazepines." <i>Tet. Lets.</i> 28(5):521-522 (1987).				
	Robl. "Synthesis of 2-(4-Fluorophenyl)-4-isopropyl-3-quinolinecarbaldehyde: A New Route to 2,3,4-Substituted Quinolines." <i>Synthesis.</i> 56-58 (1991).				
	Sato, et al. "New 1,4-Benzodiazepine-2-one Derivatives as Gastrin/ Cholecystokinin-B Antagonists." <i>Chem. Pharm. Bull.</i> 43(12): 2159-2167 (1995).				
	Satyanarayana, et al. "Carbonylation of Benzyl Halides Using CoCl ₂ /NaBH ₄ /CO/NaOH Reagent System." <i>Tet. Lets.</i> 28(23): 2633-2636 (1987).				
	Semple, et al. "Design, Synthesis, and Evolution of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors: P1-Argininal Derivatives Incorporating P3-P4 Lactam Sulfoamide Moieties." <i>J. Med. Chem.</i> 39: 4531-4536 (1996).				
	Sherrill, et al. "An Improved Synthesis and Resolution of 3-Amino-1,3 dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones." <i>J. Org. Chem.</i> 60:730-734 (1995).				
	Showell, et al. "High Affinity and Potent, Water-Soluble 5-Amino-1,4-Benzodiazepine CCKB/Gastrin Receptor Antagonists Containing a Cationic Solubilizing Group." <i>J. Med. Chem.</i> 37:719-721 (1994).				
	Smith, et al. "β-APP Processing as a Therapeutic Target for Alzheimer's Disease." <i>Current Pharmaceutical Design.</i> 3:439-445 (1997).				
	Stewart. "Syntheses of L-Kynurenine Peptides Conducted Without Masking the Side-Chain Amino Group." <i>Aust. J. Chem.</i> 33: 633-640 (1980).				
	Van Niel, et al. "CCKB Selective Receptor Ligands: Novel 1,3,5-Trisubstituted Benzazepin-2-ones." <i>Bioorganic & Medicinal Chemistry Letters.</i> 5(13):1421-1426 (1995).				
	Varnavas, et al. "Synthesis of New Benzodiazepine Derivatives as Potential Cholecystokinin Antagonists." <i>Il Farmaco.</i> 46(2):391-401 (1991).				
	Waldmann, et al. "Selective Enzymatic Removal of Protecting Groups: The Phenylacetamide as Amino Protecting Group in Phosphopeptide Synthesis." <i>Tet. Lets.</i> 37(48): 8725-8728 (1996).				
	Warshawsky, et al. "The Synthesis of Aminobenzazepinones as Anti-Phenylalanine Dipeptide Mimics and Their Use in NEP Inhibition." <i>Bioorg. & Med. Chem. Lets.</i> 6(8): 957-962 (1996).				
	Zoller, et al. "Aminoalkylation of Cercaptans with Glyoxylic Acid Derivatives." <i>Tetrahedron.</i> 31: 863-866 (1973).				
EXAMINER		DATE CONSIDERED			
Brecht Kiff		4/4/02			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

#4

#3



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTORNEY'S DKT No. 002010-586	APPLICATION No. 09/916,440
APPLICANT Jing Wu, et al.	
FILING DATE July 30, 2001	Group 1624

RECEIVED
FEB 13 2002
TECH-CENTER 1600/2900

U.S. PATENT DOCUMENTS				
Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		
B.K.	4,410,520		Watthey 424/244	10/18/83
	4,473,575		Watthey 424/263	9/24/84
	5,015,639		Berger et al. 514/213	5/14/91
	5,206,235		Fisher et al. 514/213	4/27/93
	5,247,080		Berger et al. 540/523	9/21/93
	5,486,541		Sterling et al. 514/657	1/23/96
	5,502,048		Chapdelaire et al. 514/213	3/26/96
	5,519,061		Youdim et al. 514/467	5/21/96
	5,532,415		Youdim et al. 564/308	7/2/96
	5,656,626		Chapdelaine et al. 514/213	8/12/97
	5,672,598		De et al. 514/212	9/30/97

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	no

NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

Examiner Signature <i>Bruno K...</i>	Date Considered 4/4/02
---	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.